

ARTICLE

Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups

Simeon Rüdeshcim^{1,2} | Dominik Selzer¹ | Uwe Fuhr³ | Matthias Schwab^{2,4,5} | Thorsten Lehr¹

¹Clinical Pharmacy, Saarland University, Saarbrücken, Germany

²Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, University of Tübingen, Stuttgart, Germany

³Department I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

⁴Departments of Clinical Pharmacology, Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany

⁵Cluster of Excellence iFIT (EXC2180) "Image-guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany

Correspondence

Thorsten Lehr, Clinical Pharmacy, Saarland University, Campus C2 2, 66123 Saarbrücken, Germany.
Email: thorsten.lehr@mx.uni-saarland.de

Funding information

M.S. was supported by the Robert Bosch Stiftung (Stuttgart, Germany), the European Commission Horizon 2020 UPGx grant 668353, a grant from the German Federal Ministry of Education and Research (BMBF 031L0188D), and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy—EXC 2180—390900677. T.L. was supported by the German Federal

Abstract

This study provides a whole-body physiologically-based pharmacokinetic (PBPK) model of dextromethorphan and its metabolites dextrorphan and dextrorphan *O*-glucuronide for predicting the effects of cytochrome P450 2D6 (CYP2D6) drug-gene interactions (DGIs) on dextromethorphan pharmacokinetics (PK). Moreover, the effect of interindividual variability (IIV) within CYP2D6 activity score groups on the PK of dextromethorphan and its metabolites was investigated. A parent-metabolite-metabolite PBPK model of dextromethorphan, dextrorphan, and dextrorphan *O*-glucuronide was developed in PK-Sim and MoBi. Drug-dependent parameters were obtained from the literature or optimized. Plasma concentration-time profiles of all three analytes were gathered from published studies and used for model development and model evaluation. The model was evaluated comparing simulated plasma concentration-time profiles, area under the concentration-time curve from the time of the first measurement to the time of the last measurement (AUC_{last}) and maximum concentration (C_{max}) values to observed study data. The final PBPK model accurately describes 28 population plasma concentration-time profiles and plasma concentration-time profiles of 72 individuals from four cocktail studies. Moreover, the model predicts CYP2D6 DGI scenarios with six of seven DGI AUC_{last} and seven of seven DGI C_{max} ratios within the acceptance criteria. The high IIV in plasma concentrations was analyzed by characterizing the distribution of individually optimized CYP2D6 k_{cat} values stratified by activity score group. Population simulations with sampling from the resulting distributions with calculated log-normal dispersion and mean parameters could explain a large extent of the observed IIV. The model is publicly available alongside comprehensive documentation of model building and model evaluation.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *CPT: Pharmacometrics & Systems Pharmacology* published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Ministry of Education and Research (BMBF, Horizon 2020 INSPIRATION grant 643271), under the frame of ERACoSysMed

Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?

Dextromethorphan is a substrate of cytochrome P450 2D6 (CYP2D6) and is consequently subject to considerable drug-gene interaction (DGI) effects. High interindividual variability (IIV) in dextromethorphan plasma concentrations is apparent, even within activity score groups.

WHAT QUESTION DID THIS STUDY ADDRESS?

The objective of this study was to develop a physiologically-based pharmacokinetic (PBPK) model that can describe and predict the effect of CYP2D6 DGIs on the pharmacokinetics (PK) of dextromethorphan and its metabolites dextrorphan and dextrorphan *O*-glucuronide.

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?

This study presents a PBPK model of dextromethorphan and its major metabolites that integrates current knowledge on relevant PK processes and DGIs. The model can accurately describe and predict the impact of CYP2D6 DGIs on the PK of the modeled analytes and was applied to explain a large extent of observed IIV in dextromethorphan plasma concentrations.

HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?

The developed PBPK model serves as a prototype for the development of PBPK models for other CYP2D6 substrates. Modeling provides valuable insights regarding the extent of observed overall IIV in plasma concentrations of CYP2D6 substrates as well as the observed IIV within activity score groups.

INTRODUCTION

Dextromethorphan is a widely used over-the-counter cough suppressant and a common ingredient of cold medicines marketed toward children and adults.¹ The mechanisms of action of dextromethorphan and its major metabolite dextrorphan are multifarious and include antagonism of σ 1- and *N*-methyl-D-aspartate (NMDA) receptors as well as inhibition of serotonin reuptake transporters (SERTs) and norepinephrine reuptake transporters (NERTs).² Dextrorphan has a higher affinity to NMDA receptors than dextromethorphan and is considered to be mainly responsible for the psychoactive and euphoric effects when dextromethorphan is ingested in supratherapeutic doses as a recreational drug.³

Dextromethorphan is typically administered as its hydrobromide salt, which is considered a Biopharmaceutics Drug Disposition Classification System (BDDCS) class I drug with high solubility and permeability.⁴ After oral administration, dextromethorphan is rapidly absorbed. Next, dextromethorphan undergoes an extensive first-pass metabolism, predominately mediated by CYP2D6, reducing the bioavailability to 1%–2% in CYP2D6 extensive metabolizers (EMs) and 80% in CYP2D6 poor metabolizers (PMs).⁵ Unbound dextromethorphan accounts for 35% of the total drug plasma concentration.²

Dextromethorphan-*O*-demethylation via CYP2D6 leads to the formation of the major active metabolite dextrorphan. Dextrorphan subsequently undergoes rapid glucuronidation via uridine diphosphate-glucuronosyltransferases 2B (UGT2Bs), namely UGT2B15, or *N*-demethylation via CYP3A4.⁶ Alternatively, dextromethorphan is *N*-demethylated by CYP3A4, which was found to be the main pathway of dextromethorphan metabolism in CYP2D6 PMs.² Depending on the CYP2D6 phenotype, up to 50% of orally administered dextromethorphan is excreted unchanged in urine.^{5,7} Because the *CYP2D6* gene is prone to genetic alterations, dextromethorphan pharmacokinetics (PK) is subject to considerable drug-gene interaction (DGI) effects. For instance, the dextromethorphan area under the plasma concentration-time curve (AUC) in CYP2D6 PMs was reported to be 26-fold higher than that of CYP2D6 EMs.⁸ Hence, the US Food and Drug Administration (FDA) lists dextromethorphan as a sensitive substrate of CYP2D6 and recommends its usage in clinical drug-drug interaction studies and dextromethorphan *O*-demethylation as an *in vitro* marker reaction for CYP2D6 metabolism.⁹ Furthermore, the dextromethorphan/dextrorphan metabolic ratio is frequently used to determine the CYP2D6 phenotype *in vivo*.^{10,11} Hence, dextromethorphan is frequently included in different phenotyping cocktails.^{12,13}

To date, more than 140 alleles of the *CYP2D6* gene are known, some of which have only been discovered in recent years.¹⁴ With well over 10,000 potential *CYP2D6* diplotypes, investigating the effect of every genotype on a drug's PK is an unfeasible task for clinical researchers.¹⁵ Consequently, an activity score system is in place to facilitate the process of translating the *CYP2D6* diplotype into a patient's phenotype.^{15,16} This process has since been harmonized between pharmacogenomics laboratories and between clinical guidelines of the Dutch Pharmacogenomics Working Group (DPWG) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).¹⁷ Here, a patient's activity score is defined as the sum of activity values assigned to the patient's alleles with values encoding for no (0), decreased (0.25–0.5), or normal function (1), or a copy number variation of a normal function allele (>2).¹⁵ The activity score system is an eminently useful concept for grouping study subjects based on their genotypes. However, a large interindividual variability (IIV) in the PK of *CYP2D6* substrates in subjects with an identical activity score remains largely unexplained and requires further research.¹⁶

The objectives of this study were (1) to develop and evaluate a physiologically-based pharmacokinetic (PBPK) parent-metabolite DGI model of dextromethorphan, dextrophan, and dextrophan *O*-glucuronide, (2) to describe the effects of different *CYP2D6* activity scores on the PK of dextromethorphan by implementing specific *CYP2D6* activity score-dependent metabolic processes, and (3) to apply the developed model to explain the observed IIV in individual subjects sharing the same *CYP2D6* activity score. The final PBPK model will be publicly available in the Open Systems Pharmacology (OSP) repository (www.open-systems-pharmacology.org)¹⁸ as a clinical research tool. Moreover, the Supplementary document (Supplementary S1) to this article provides an in-depth evaluation of the model performance and can be used as a model reference manual.

METHODS

Software

The dextromethorphan PBPK model was developed using PK-Sim and MoBi (Open Systems Pharmacology Suite 9.1, www.open-systems-pharmacology.org). Model parameter optimizations via Monte Carlo algorithm and local sensitivity analyses were conducted in PK-Sim. Published clinical study data were digitized according to the recommended practice¹⁹ using GetData Graph Digitizer 2.26.0.20 (© S. Fedorov). PK parameters, model performance metrics, and plots were calculated and generated using Python (version 3.9.1; Python Software Foundation,

Wilmington, DE). Regression analyses were performed using ordinary least squares utilizing the *statsmodels* package (version 0.12.2) in Python.²⁰

Clinical study data

Published clinical studies were obtained from the literature, including aggregated plasma concentration-time profiles after intravenous and oral administrations in single and multiple dose regimens of dextromethorphan alone or various phenotyping cocktails. It was assumed that there were no relevant mutual interactions between the cocktail compounds affecting dextromethorphan PK.^{12,21} The composition of phenotyping cocktails used in the respective studies is provided in Section S1.1 of Supplementary S1. All collected dextromethorphan plasma concentration-time profiles were split into a training dataset, for model building and a test dataset, for model evaluation. Studies for model training were selected to include different routes of administration (intravenous and oral), a wide range of administered doses as well as data covering all investigated *CYP2D6* genotypes or activity scores. The training dataset was used for estimation of model input parameters which could not be obtained from the literature. Studies were complemented by individual dextromethorphan, dextrophan, and total dextrophan (dextrophan and dextrophan *O*-glucuronide) plasma profiles from 72 study participants. The respective data was reported in a PhD thesis by Frank in 2009 as a compilation of four clinical cocktail studies (studies A–E).²² Study B was excluded from the dataset due to inconsistencies between the reported individual genotypes and the corresponding plasma concentrations of dextromethorphan, which may be explained by the limited set of genetic *CYP2D6* variants assessed (see Section S6.1 of Supplementary S1 for a detailed analysis). Sections S2.2, S4.2, and S6.3 of Supplementary S1 provide comprehensive information on population and individual demographics (sex, age, weight, and height), analyzed compounds, *CYP2D6* activity (*CYP2D6* phenotype, genotype, and activity score, if available), drug dosing regimens and the assignment to the respective test and training datasets for all modeled studies and individual profiles.

PBPK base model building

The dextromethorphan PBPK model building process started with an extensive literature search to obtain physicochemical data on dextromethorphan, dextrophan, and dextrophan *O*-glucuronide as well as information on absorption, distribution, metabolism, and excretion. The

dextromethorphan PBPK model was developed using individual simulations based on typical mean individuals for the respective study populations (see Section S1.3 of Supplementary S1). First, a combination of quantitative structure-activity relationship methods implemented in PK-Sim was selected for the estimation of cellular permeabilities and organ/plasma partition coefficients. Here, the selection of the optimal combination was based on the minimum residual error for parameter estimations fitting intravenous dextromethorphan administration simulations to their respective observed data. Subsequently, studies of orally administered dextromethorphan in PMs were used to optimize model parameters independent of CYP2D6 metabolism, as the CYP2D6 activity of poor metabolizers was assumed to be 0% due to the lack of expression of functional CYP2D6 protein in carriers of two CYP2D6 loss-of-function alleles (e.g., *CYP2D6**3, *4, and *6).¹⁰ Finally, CYP2D6 catalytic rate constant (k_{cat}) values were optimized for EMs by fitting to EM plasma concentration-time profiles of the training dataset. Here, the historical term “extensive metabolizer” was used to describe populations which were either not phenotyped or phenotyped via classical phenotyping methods, such as measurements of metabolic ratios or screening for *CYP2D6* null alleles. Genotyped populations possessing activity scores ranging from 1.25–2.25 were considered “normal metabolizers.”¹⁷

Overall, the minimal number of processes necessary to mechanistically describe the PK of dextromethorphan, dextrorphan, and dextrorphan *O*-glucuronide were implemented to limit the number of unknown parameter values to be optimized. Total dextrorphan was calculated as the sum of simulated dextrorphan and dextrorphan *O*-glucuronide. System-dependent parameters and details on the implementation of CYP2D6, CYP3A4, and UGT2B15 are presented in Section S7 of Supplementary S1.

PBPK model evaluation

Performance of the PBPK model regarding the prediction of dextromethorphan and its metabolites dextrorphan and dextrorphan *O*-glucuronide was evaluated using graphical and statistical methods.

First, simulated population plasma concentrations (arithmetic mean \pm SD) were compared graphically to observed data of the respective clinical studies. For this, virtual populations of 1000 individuals were created using the mode of reported sex and ethnicity as well as mean values for age, weight, and height from each study protocol. Sections S1.3 and S1.4 of Supplementary S1 provide a comprehensive description of virtual individuals and virtual populations.

Second, the arithmetic mean of population simulations or individual predictions for all plasma concentration-time profiles were plotted against their corresponding observed values in goodness-of-fit plots.

Third, predicted and observed AUC values and maximum plasma concentration (C_{max}) values were graphically compared. Here, all AUC values (predicted as well as observed) were calculated from the time of the first measurement to the time of the last measurement (AUC_{last}).

Finally, as quantitative measures of the model performance, the mean relative deviation (MRD) of all predicted plasma concentrations (Equation 1) and the geometric mean fold error (GMFE) of all predicted AUC_{last} and C_{max} values (Equation 2) were calculated.

$$\text{MRD} = 10^x; x = \sqrt{\frac{\sum_{i=1}^k (\log_{10} \hat{c}_i - \log_{10} c_i)^2}{k}} \quad (1)$$

where \hat{c}_i = predicted plasma concentration that corresponds to the *i*-th observed concentration, c_i = *i*-th observed plasma concentration, k = number of observed values.

$$\text{GMFE} = 10^x; x = \frac{\sum_{i=1}^m \left| \log_{10} \left(\frac{\hat{p}_i}{p_i} \right) \right|}{m} \quad (2)$$

where \hat{p}_i = predicted AUC_{last} or C_{max} value of study p_i = corresponding observed AUC_{last} or C_{max} value of study i , m = total number of studies.

Local sensitivity of the $\text{AUC}_{0-24\text{h}}$ of dextromethorphan, dextrorphan, and dextrorphan *O*-glucuronide to single parameter changes was analyzed for a simulation of 30 mg orally administered dextromethorphan hydrobromide as a single dose (standard dose). Parameters were included if they have been optimized (k_{cat} values and dextromethorphan intestinal permeability), if they are associated with optimized parameters (K_M values) or if they might have a strong impact due to calculation methods used (lipophilicity, fraction unbound, and pK_a values). A detailed description is provided in Section S1.6 of Supplementary S1 and a list of all parameters included in the sensitivity analysis is given in Section S3.6 of Supplementary S1.

DGI model building

The principal pathway of dextromethorphan metabolism is the CYP2D6-mediated *O*-demethylation, leading to the formation of dextrorphan. This pathway was implemented using Michaelis-Menten kinetics according to Equation 3²³:

$$V = \frac{V_{\text{max}} \cdot S}{K_M + S} = \frac{k_{\text{cat}} \cdot E \cdot S}{K_M + S} \quad (3)$$

where v = reaction velocity at substrate concentration S , V_{\max} = maximum reaction velocity, K_M = Michaelis-Menten constant, k_{cat} = catalytic rate constant, and E = enzyme concentration.

For DGI modeling, the CYP2D6 Michaelis-Menten constant (K_M) values for the dextromethorphan *O*-demethylation were kept constant over the whole range of modeled activity scores.²⁴ CYP2D6 k_{cat} values were optimized separately for each activity score. CYP2D6 PMs (activity score = 0) were assumed to show no CYP2D6 activity (0%), whereas populations with two wildtype alleles (activity score = 2) were assumed to possess normal CYP2D6 activity (100%). Activity scores were assigned according to Caudle et al.¹⁷

DGI model evaluation

Modeled DGIs were evaluated by comparison of predicted versus observed plasma concentration-time profiles of dextromethorphan and its metabolites. Plasma concentration-time profiles for populations displaying variant phenotypes were compared to those of the EM phenotype, whereas plasma concentration-time profiles for populations with a variant activity score were compared to profiles of a population with normal activity (activity score = 2) in studies reporting activity scores or genotypes. Similarly, predicted DGI AUC_{last} ratios (Equation 4) and DGI C_{max} ratios (Equation 5) were evaluated for study populations with different CYP2D6 activity scores or phenotypes.

$$\text{DGI } AUC_{\text{last}} \text{ ratio} = \frac{AUC_{\text{last, DGI}}}{AUC_{\text{last, reference}}} \quad (4)$$

Here, $AUC_{\text{last, DGI}}$ = AUC_{last} of variant activity score or phenotype, $AUC_{\text{last, reference}}$ = AUC_{last} of activity score = 2 or EM phenotype.

$$\text{DGI } C_{\text{max}} \text{ ratio} = \frac{C_{\text{max, DGI}}}{C_{\text{max, reference}}} \quad (5)$$

with $C_{\text{max, DGI}}$ = C_{max} of variant activity score or phenotype, $C_{\text{max, reference}}$ = C_{max} of activity score = 2 or EM phenotype.

Additionally, GMFE values of the predicted DGI AUC_{last} ratios and DGI C_{max} ratios were calculated according to Equation 2 as a quantitative measure of prediction accuracy.

Assessment of interindividual variability within activity score groups

To assess the impact of IIV on the PK of dextromethorphan, CYP2D6 k_{cat} values were optimized separately, using their respective observed data, for all individual plasma

concentration-time profiles of the four cocktail studies. Activity scores for all genotyped subjects were calculated according to Caudle et al.¹⁷ Subjects with the same activity scores were grouped and geometric means and standard deviations were calculated from the optimized individual CYP2D6 k_{cat} values. Subsequently, these values were graphically compared to the population k_{cat} values, obtained in the model building process. Finally, an ordinary least squares regression analysis was applied between individual optimized k_{cat} and their population k_{cat} counterpart for the respective activity score.

RESULTS

PBPK base model building

The dextromethorphan PBPK model was developed using a total of 28 clinical studies where dextromethorphan was administered as an intravenous infusion (one study), orally in single (26 studies), or multiple doses (one study), alone (17 studies) or as part of a phenotyping cocktail (11 studies). Doses ranged between 5 and 80 mg of administered dextromethorphan. Table 1 provides an overview of demographics and CYP2D6 activity for all modeled studies.

For dextromethorphan, the PBPK model implements metabolism via CYP2D6 (leading to the formation of dextrophan) and CYP3A4 as well as excretion via passive glomerular filtration. To emulate the effect of lysosomal trapping in the gastrointestinal mucosa,^{25,26} a binding process was included in the model that is comprehensively described in Section S1.5 of Supplementary S1.

The primary metabolite dextrophan is metabolized via CYP3A4 and UGT2B15. The latter serves as a surrogate pathway in the model for the glucuronidation via multiple UGT2B enzymes, as UGT2B15 was reported to have the largest contribution of all involved UGTs.⁶ Dextrophan *O*-glucuronide is renally eliminated via passive glomerular filtration and active secretion to the urine. Other dextromethorphan metabolites, such as 3-methoxymorphinan or 3-hydroxymorphinan, were not included as model compounds due to the limited number of published plasma concentration-time profiles for these analytes.

An overview of the implemented model compounds and pathways is provided in Figure 1. For dextromethorphan, dextrophan, and dextrophan *O*-glucuronide, the drug-dependent model input parameters are provided in Section S2.1 of Supplementary S1.

PBPK base model evaluation

Overall, the PBPK model accurately predicted dextromethorphan, dextrophan, and dextrophan *O*-glucuronide plasma

TABLE 1 Summary of demographic parameters and CYP2D6 activity for all modeled studies

	Dataset I: Base model building and evaluation		Dataset II: DGI model building and evaluation		Dataset III: Studies reporting individual data				
	A	B	C	D	E	F	G	H	I
Number of studies	15	13							
Number of individuals	309	120	16	12	16	12	12	28	
Demographics									
Females, %	27	37	0	0	0	0	0	25	
Age, years	31 (19–74)	26 (18–55)	29 (23–42)	36 (24–49)	29 (21–43)	32 (18–48)	40 (25–60)		
Weight, kg	74 (49–110)	69 (60–79)	78 (65–101)	80 (60–103)	80 (66–99)	72 (60–82)	72 (49–106)		
Height, cm	*	*	182 (171–195)	181 (165–198)	182 (173–194)	180 (171–190)	174 (156–190)		
CYP2D6 activity									
Phenotype ^a									
PM	1	2	1	1	–	–	1	1	
IM	–	3	7	5	2	4	–	13	
EM	14	2	–	–	4	1	–	–	
NM	–	6	4	6	9	7	–	13	
UM	–	–	2	–	1	–	–	1	
Activity score ^a									
0	–	–	1	1	–	–	–	1	
0.25	–	2	1	–	–	–	–	–	
0.5	–	2	–	1	1	–	–	–	
1	–	1	7	3	1	4	–	13	
1.25	–	2	–	–	–	–	–	–	
1.5	–	–	1	1	4	2	–	–	
2	–	4	4	5	4	5	–	13	
3	–	–	2	–	1	–	–	1	
Dextromethorphan observed AUC_{C_{last}}, ng·h/ml									
Phenotype									
PM	981.2	756.7 (547.7)							
EM	39.2 (30.1)	40.4 (25.8)							

TABLE 1 (Continued)

Activity score	Dataset I: Base model building and evaluation		Dataset II: DGI model building and evaluation		Dataset III: Studies reporting individual data		
	A	B	C	D	E	D	E
0	162.4	3.1					97.6
0.25	146.3						
0.5		3.9 (2.5)	63.7				
1	5.7 (1.5)	8.2 (5.2)	5.1	14.6 (15.3)			36.4 (57.4)
1.25			22.0 (1.1)				
1.5	17.3	5.9		16.4 (16.2)			
2	0.6 (0.5)	49.3 (53.6)		4.3 (5.2)			8.7 (7.0)
3	0.4 (0.2)						2.3

Note: AUC_{last} values are given as arithmetic mean (SD), demographic parameters are given as mean (range). *Insufficient data available to calculate mean values; -, not available, ^agiven as mode of every study for datasets I and II, or number of individuals with the respective activity score for dataset III.

Abbreviations: AUC_{last}^a, area under the plasma concentration-time curve from the time of the first concentration measurement to the time of the last concentration measurement; DGI, drug-gene interaction.

concentrations after intravenous and oral administration with a selection of predicted compared to observed plasma concentration time-profiles presented in Figure 2. The simulations of all 28 modeled population studies are shown in sections S3.1 and S5.1 of Supplementary S1.

Goodness-of-fit plots comparing predicted and observed plasma concentrations, AUC_{last} and C_{max} values are presented in Figure 3. Overall, 70.6% of predicted plasma concentrations were within the two-fold range of the corresponding observed concentrations. Furthermore, 35 of 42 of the predicted AUC_{last} values (several studies included measurements of multiple analytes) and 35 of 41 of the predicted C_{max} values were within two-fold range with model GMFE values of 1.53 (range 1.01–3.45) for predicted AUC_{last} and 1.46 (range 1.01–2.97) for predicted C_{max} values. MRD values of predicted plasma concentrations as well as AUC_{last} and C_{max} ratios for all 28 clinical studies and all measured analytes are provided in sections S3.3, S3.5, S5.3, and S5.5 of Supplementary S1.

A simulation of 30 mg dextromethorphan hydrobromide administered orally (standard dose) was used for local sensitivity analysis. Parameters with associated sensitivity values greater than 0.5 (100% parameter value perturbation resulting in a greater than 50% change of predicted AUC) were considered sensitive. Sensitive parameters were, in order of highest to lowest impact, f_u (literature value), CYP2D6 k_{cat} (optimized value), lipophilicity (literature value), CYP2D6 K_M (literature value), and intestinal permeability (optimized value). A quantitative and visual representation of the local sensitivity analysis is provided in Section S3.6 of Supplementary S1.

DGI model building

The DGI model training dataset consisted of four studies that reported CYP2D6 activity scores or genotypes of their respective study populations. To complement these studies, 24 individual plasma concentration-time profiles were included. The assignment of studies and individual profiles to the respective datasets is listed in sections S4.2 and S6.3 of Supplementary S1.

Overall, activity scores in the DGI model training dataset ranged from 0 (PM) to 3 (ultrarapid metabolizer) and covered a total of eight activity scores. This dataset was used to optimize population k_{cat} values for the activity scores of the respective studies or individual profiles (see Section S4.1 of Supplementary S1).

DGI model evaluation

The DGI model was evaluated using a total of 13 clinical population studies, which stratified their subjects by




FIGURE 1 Implemented dextromethorphan metabolic pathways. Dextromethorphan is *O*-demethylated by CYP2D6 and *N*-demethylated by CYP3A4. The metabolite dextrorphan is further metabolized via CYP3A4 (*N*-demethylation) and UGT2B15 (*O*-glucuronidation). Dextrorphan *O*-glucuronide is excreted in the urine. Percentages shown refer to the fraction metabolized by the respective enzyme, calculated for extensive metabolizers of CYP2D6. CYP2D6: cytochrome P450 2D6, CYP3A4: cytochrome P450 3A4, UGT2B15: Uridine 5'-diphospho-glucuronosyltransferase 2B15

CYP2D6 activity score or phenotype. These studies either provided the CYP2D6 phenotype (4 studies) or comprehensive information on the *CYP2D6* genotype of individuals (9 studies). Simulations were performed using the corresponding k_{cat} values with respect to activity score (Section S4.1 of Supplementary S1) or phenotype (Section S2.1 of Supplementary S1).

The good performance of the final dextromethorphan DGI model is demonstrated in Figure 4a–e depicting predicted dextromethorphan plasma concentration-time profiles of populations with different activity scores compared to their respective observed data. Plots documenting the model performance of all 15 DGI studies are provided in Section S5.1 of Supplementary S1.

Predicted DGI AUC_{last} and C_{max} ratios were in good agreement with observed DGI ratios, demonstrating that the effect of different CYP2D6 activity scores on the PK of dextromethorphan and dextrorphan was well-described by the model. Specifically, six of seven AUC_{last} and six of six C_{max} ratios were within the prediction success limits suggested by Guest et al. adopted for DGI evaluations,²⁷ as visualized in Figure 4f,g. The predicted DGI AUC_{last} ratios showed an overall GMFE of 1.45 (range 1.04–2.84) and the overall GMFE of predicted DGI C_{max} ratios was calculated as 1.21 (range 1.02–1.40). Predicted to observed DGI AUC_{last} and C_{max} ratios for all studies are provided in Section S5.5 of Supplementary S1. Predictions of dextromethorphan, dextrorphan, and dextrorphan *O*-glucuronide exposure in individuals with different activity scores after a single oral dose of 30 mg dextromethorphan hydrobromide and a comparison of the corresponding AUC values are given in Figure 5.

Interindividual variability within activity score groups

The individual profiles from four cocktail studies were used to assess the extent of IIV within activity score groups. For 66 of the 72 study subjects, the *CYP2D6* genotype was provided. Six subjects were not genotyped and consequently excluded from this analysis.

The distribution of activity scores from the dataset is listed in Section S6.2 of Supplementary S1. Plasma concentration-time profiles of dextromethorphan, dextrorphan, and total dextrorphan were simulated using the population k_{cat} values given in Section S4.1 of Supplementary S1. Additionally, the profiles were simulated using individually optimized k_{cat} values and the geometric mean with geometric standard deviation of the individual k_{cat} values were calculated for all activity score groups with n greater than 2 (see Section S6.2 of Supplementary S1).

A representative selection of predictions using individual and model CYP2D6 k_{cat} values is visualized in Figure 6. Furthermore, Section S6.4 of Supplementary S1 includes plots with model and individual predictions for all 66 genotyped individuals alongside model predictions for the six non-genotyped individuals. The latter were simulated using the population k_{cat} value for EMs (see Section S2.1 of Supplementary S1).

The predictive performance using model k_{cat} was compared to using the individual optimized k_{cat} values by calculating the GMFE for all individual plasma concentration-time profiles (see Sections S6.7, S6.8, and S8 of Supplementary S1). Generally, model performance improved for simulations of dextromethorphan and





FIGURE 2 Dextromethorphan and dextrorphan plasma concentrations. Model predictions of dextromethorphan and its metabolites dextrorphan and dextrorphan *O*-glucuronide as well as total dextrorphan (dextrorphan + dextrorphan *O*-glucuronide) plasma concentration-time profiles of selected intravenous (a) and oral studies (b–i) from the training and test datasets, compared to observed data.^{7,8,45–51} Population predictions ($n = 1000$) are shown as lines with ribbons (arithmetic mean \pm SD), symbols present the corresponding observed data \pm SD. Detailed information on all clinical studies is listed in sections S2.2 and S4.2 of Supplementary S1. iv, intravenous; po, oral

dextrorphan plasma concentration-time profiles using the individually optimized k_{cat} when compared to simulations, where population k_{cat} values were used across all activity scores and analyzed studies. However, total dextrorphan AUC_{last} and C_{max} values were markedly underpredicted for studies D and E (GMFEs of 3.93 and 3.28 for study D and 2.81 and 2.69 for study E) compared to

studies A and C (GMFEs of 1.30 and 1.44 for study A and 1.20 and 1.24 for study C). Predicted to observed AUC_{last} and C_{max} ratios for all individual simulations using the model k_{cat} and the individual optimized k_{cat} are listed in Section S6.7 of Supplementary S1. Section S6.8 of Supplementary S1 gives a detailed breakdown of AUC_{last} and C_{max} ratios grouped by study and activity score.

FIGURE 3 Goodness-of fit plots for the final dextromethorphan model. Predicted versus observed plasma concentrations (a, b), AUC_{last} values (c, d) and C_{max} values (e, f) for the training (left column) and test (right column) datasets. The solid black line indicates the line of identity, solid gray lines show two-fold deviation, dashed gray lines indicate 1.25-fold deviation. Detailed information on all clinical studies is listed in sections S2.2 and S4.2 of Supplementary S1. AUC_{last} , area under the plasma concentration-time curve from the time of the first concentration measurement to the time of the last concentration measurement; C_{max} , maximum plasma concentration, dextromethorphan-total: sum of dextromethorphan and dextromethorphan *O*-glucuronide concentrations



Moreover, the optimized individual k_{cat} values for the different activity score groups were plotted against their activity score to visualize the distribution of individual k_{cat} values in the respective activity score groups (see Figure 7a). A regression analysis of model k_{cat} values compared to the geometric mean of optimized individual k_{cat} values revealed a high correlation ($R^2 = 0.9988$). Consequently, the individual profiles were sufficiently well-described with the model k_{cat} values. The results of the regression analysis are illustrated in Figure 7b.

Finally, population simulations were performed with sampling from a log-normal distribution with mean and dispersion parameters calculated from the samples of optimized individual k_{cat} values (see Section S6.2 of Supplementary S1) to analyze the simulated coverage of IIV observed in dextromethorphan plasma concentrations from the study populations.

Subsequently, predictions were compared graphically in population simulations with no variability of the

CYP2D6 population k_{cat} . As expected, model predictions including the k_{cat} variability improved describing the large extent of IIV within an activity score group compared to predictions with no variability on the CYP2D6 k_{cat} (see Figure 7c-f).

DISCUSSION

In this study, a whole-body PBPK model of dextromethorphan and its metabolites dextromethorphan and dextromethorphan *O*-glucuronide was developed and evaluated to predict drug plasma concentrations over a wide dosing range (5–80 mg). A CYP2D6 activity score-dependent metabolism of dextromethorphan was implemented to describe the effect of CYP2D6 DGIs on the PK of the modeled compounds. Moreover, the model was applied to investigate the IIV of dextromethorphan PK within different activity score groups.




FIGURE 4 Simulated dextromethorphan and dextroprhan plasma concentrations and DGI ratios for different CYP2D6 activity scores. Upper panel: Dextromethorphan (a–c) as well as Dextromethorphan and dextroprhan (d, e) plasma concentration–time profiles of selected dextromethorphan CYP2D6 DGI studies, compared to observed data.^{52,53} Population predictions ($n = 1000$) are shown as lines with ribbons (arithmetic mean \pm SD), symbols present the corresponding observed data \pm SD. Lower panel: comparison of predicted versus observed DGI AUC_{last} ratios (f) and DGI C_{max} ratios (g) for all analyzed dextromethorphan CYP2D6 DGI studies. The straight black line indicates the line of identity, curved black lines show prediction success limits proposed by Guest et al. including 1.25-fold variability.²⁷ Solid gray lines indicate two-fold deviation, dashed gray lines show 1.25-fold deviation. Detailed information on all DGI studies as well as the plotted values are given in section S4.1 and S5.4 of Supplementary S1, respectively. AS, activity score; AUC, area under the plasma concentration–time curve; AUC_{last}, AUC from the time of the first concentration measurement to the time of the last concentration measurement; C_{max}, maximum plasma concentration; DGI, drug–gene interaction; po, oral




FIGURE 5 Predicted dextromethorphan, dextrorphan and dextrorphan *O*-glucuronide exposure in individuals with different activity scores. Simulations were performed for a single oral dose of 30 mg dextromethorphan hydrobromide in healthy male individuals. Top row: dextromethorphan (a), dextrorphan (b) and dextrorphan *O*-glucuronide (c) plasma concentrations. Bottom row: Dextromethorphan (d), dextrorphan (e) and dextrorphan *O*-glucuronide (f) AUC_{0-24h} values for different activity scores. AUC, area under the plasma concentration-time curve

Three previously published PBPK models of dextromethorphan were found in the literature that focused on different aspects of PBPK modeling, specifically cross-species modeling,²⁸ investigation of pregnancy effects,²⁹ and the impact of formulations (and, by extension, lysosomal trapping)²⁶ on dextromethorphan pharmacokinetics. Two studies included either dextrorphan²⁹ or dextrorphan and dextrorphan *O*-glucuronide²⁶ as model compounds. These studies also included “traditional” phenotypes (EMs and PMs) in the model and did not further differentiate between CYP2D6 activity scores. Consequently, our model is the first whole-body

parent-metabolite-metabolite PBPK model of dextromethorphan, aiming to investigate the effect of CYP2D6 activity scores on dextromethorphan PK, with a total of eight different activity scores implemented.

In our model, the dextromethorphan CYP2D6 DGIs were described without explicitly modeling distinct *CYP2D6* genotypes. Although a wide variety of relevant genotype-specific in vitro parameters, such as K_M and V_{max} are available in the literature,³⁰⁻³² implementing all possible genotypes using a genotype-specific approach would be infeasible due to the large (and still growing) amount of known CYP2D6 alleles.³³ Thus, a CYP2D6 activity

FIGURE 6 Dextromethorphan and dextrorphan plasma concentrations for individuals of several activity score groups. Selected dextromethorphan, dextrorphan, and total dextrorphan (dextrorphan + dextrorphan *O*-glucuronide) plasma concentration-time profiles compared to observed data reported by Frank 2009.²² Predictions are shown as lines. Solid lines represent model predictions, dotted lines represent individual predictions. Symbols present the corresponding observed data. Detailed information on all individual profiles is listed in Sections S6.1, S6.2, and S6.3 of Supplementary S1. AS, activity score; po, oral





FIGURE 7 Analysis of optimized individual CYP2D6 k_{cat} values for the different activity scores and population simulations for different activity score groups. (a) Box- and scatterplots for optimized individual k_{cat} values in the respective activity score groups. Boxes represent interquartile ranges, lines within boxes represent median values. (b) Comparison of model k_{cat} and optimized geometric mean k_{cat} values and regression analysis. Colored circles represent the geometric mean k_{cat} value for an activity score group compared to the population k_{cat} value. Error bars represent the geometric standard deviation. Simulations were performed with the population k_{cat} values using a standard administration protocol (a single dose of 30 mg dextromethorphan hydrobromide) for populations with an CYP2D6 activity score of 1 (c), 1.5 (d), 2 (e), and 3 (f) with no variability and variability (calculated geometric standard deviation) on the CYP2D6 population k_{cat} . Population predictions ($n = 1000$) are represented as lines with ribbons (geometric mean with geometric standard deviation), symbols represent the corresponding observed data (geometric mean with geometric standard deviation) for the population reported by Frank 2009.²² AS, activity score; CYP2D6, cytochrome p450 2D6; dxt, dextrorphan; k_{cat} , catalytic rate constant; R^2 , coefficient of determination



score-specific approach was developed. As a result, this PBPK model cannot further differentiate between different genotypes within the same activity score group, for instance, *CYP2D6**1/*1 and *CYP2D6**2/*2. However, the model could be readily extended to include a genotype-specific *CYP2D6* metabolism in the future.

Moreover, *CYP2D6* metabolism for different activity scores was implemented with a fixed K_M literature value⁶ for all covered activity scores. However, in vitro data shows that K_M may vary between different genotypes and activity scores.^{31,32,34} Nonetheless, a study investigating the effect of activity scores on the *CYP2D6*-dependent metabolism of dextromethorphan in vitro found no significant correlation between activity score and *CYP2D6* K_M .³⁰ Most studies reported a reduction of *CYP2D6*-dependent clearance (CL_{int} and V_{max}/K_M) when comparing reduced function alleles (*10 and *17) to the wildtype *1 allele.^{30–32} Additionally, analyses of *CYP2D6* content in HLMs showed a high positive correlation between *CYP2D6* abundances and activity score, albeit substantial IIV in *CYP2D6* content within activity score groups and even in groups sharing the same *CYP2D6* diplotype has been observed.¹⁶ These trends in *CYP2D6* content in HLMs and *CYP2D6* CL_{int} are reflected in the final dextromethorphan PBPK model with higher *CYP2D6* activity scores inferring higher population k_{cat} values (see Section S4.1 of Supplementary S1). A similar modeling approach was also utilized for previously developed PBPK models of *CYP2D6* substrates.²⁴ The *CYP2D6* k_{cat} value for populations grouped as EMs was observed to be lower than for genotyped normal metabolizers with activity scores ranging from 1.25–2.25 (compare sections S2.1 and S4.1 of Supplementary S1). Typically, study subjects in the literature were either phenotyped via measurements of urinary metabolic ratio, often using arbitrary cutoff points for poor metabolizers,¹⁵ or via screening for null alleles.³⁵ Thus, there is only a limited intersection between the broad EM phenotype category and the genetically determined NMs.³⁶ Overall, the presented model was able to accurately describe DGI AUC_{last} and C_{max} ratios as well as the plasma concentration-time profiles of all analyzed clinical studies.

The final dextromethorphan PBPK model was applied to investigate the effect of IIV on the PK of dextromethorphan with a total of 72 individual plasma concentration-time profiles of dextromethorphan, dextrorphan, and total dextrorphan. A substantial variability was observed within activity scores 1–3 (geometric standard deviation range of 1.29–2.52). For activity scores less than 1, the number of individual profiles per score (less than 5) was insufficient to make meaningful assessments of the IIV. The large extent of IIV in the PK of *CYP2D6* substrates within activity score groups or even within subjects possessing the

same *CYP2D6* genotype, is a well-documented phenomenon.¹⁶ A twin study on the heritability of metoprolol PK, concluded that genetic components independent of the *CYP2D6* gene may be responsible for the IIV in *CYP2D6* activity.³⁷ Indeed, the rs5758550 single-nucleotide polymorphism (SNP) was identified as an enhancer SNP and may, in the future, even lead to a reclassification of activity scores based on *CYP2D6* and rs5758550 genotype.³⁸ Currently published literature lacks clinical in vivo studies describing the effect of the rs5758550 genotype on the PK of dextromethorphan. Other genetic factors, such as regulation of *CYP2D6* expression via transcription factors or miRNA, are also likely to contribute to IIV and intraindividual variability.¹⁶ Additionally, genetic and non-genetic variability in enzymes other than *CYP2D6* are expected to contribute to the IIV in dextromethorphan PK, specifically for *CYP2D6* PMs, as the fraction metabolized by *CYP2D6* decreases for dextromethorphan from greater than 95% for EMs⁵ to 0% for PMs of *CYP2D6*,¹⁰ consequently increasing the fraction of dextromethorphan metabolized by *CYP3A4*. Additionally, IIV can be observed in plasma concentrations of dextrorphan and dextromethorphan *O*-glucuronide, possibly caused by variability in *CYP3A4* and *UGT* enzymes. As genotypic data for *CYP3A* and *UGT* was unavailable for study subjects, the analysis of IIV was performed for dextromethorphan plasma concentrations purely in the context of *CYP2D6* activity score groups. However, as new data emerges, the presented PBPK model can mechanistically be adapted to describe these genotypic effects of *CYP2D6* and other pharmacogenes affecting the PK of dextromethorphan and its metabolites. A large extent of IIV in plasma concentrations and *CYP2D6* activity was observed and quantified in this study. To reflect this in the model, the distributions of *CYP2D6* k_{cat} values for activity scores 1, 1.5, 2, and 3 were characterized from k_{cat} optimizations in 72 individuals to improve population predictions, as demonstrated in Figure 7c–f, and may be used in future PBPK models of *CYP2D6* substrates.

To supplement the limited number of studies in which dextromethorphan was administered alone (14 studies), studies in which dextromethorphan was administered as part of a phenotyping cocktail (11 studies and the studies compiled by Frank et al.²²) were included in the model dataset. All modeled cocktail studies administered either the “Cologne” cocktail,^{21,39} the “Cooperstown 5+1”¹² cocktail, or minor variations thereof (see Section 1.1 of Supplementary S1). No relevant mutual interactions have been observed for these cocktails, although sample sizes for these assessments were often small.²¹ Additionally, assessments of these interactions are generally concerned with the effect of the cocktail on primary pathways of the cocktail compounds (i.e., dextromethorphan *O*-demethylation).⁴⁰ Here, additional in vitro experiments

are needed to evaluate possible effects of phenotyping cocktails on other model pathways, such as dextropran O-glucuronidation. Overall, plasma concentration-time profiles were well-predicted for all population studies regardless of whether dextromethorphan was administered alone or as part of a phenotyping cocktail (see Sections S3.1–S3.5 and Sections S5.1–S5.5).

Overall, model predictions were considered adequate for all population studies regardless of whether the study was a cocktail study or not (see Sections S3.2–S3.5 and S5.2–5.7 of Supplementary S1). For studies reporting individual plasma concentration-time profiles, the model performed comparably well across all activity scores. However, a large interstudy variability was observed for dextromethorphan and total dextropran AUC_{last} and C_{max} values (see Section S6.8 of Supplementary S1). For instance, studies D and E reported up to four-fold higher AUC_{last} and C_{max} values for total dextropran compared with studies A and C. As these studies were comparable in study design, cocktail composition, and sample analysis, as well as dextromethorphan and dextropran plasma concentrations, this apparent discrepancy was attributed to relatively small study cohorts and the large extent of IIV in CYP2D6 activity (see Figure 7a,b) described in the published literature.¹⁶

Finally, the developed and evaluated PBPK model of dextromethorphan is a useful tool for clinicians to investigate the effect of CYP2D6 DGIs and the associated IIV on the PK of dextromethorphan and its metabolites. The mechanistical model can be extended to be used in other PBPK modeling scenarios, such as the prediction of drug-drug interaction and DGI effects⁴¹ and scaling to special populations, such as pediatrics,⁴² geriatrics,⁴³ or patients with renal or hepatic impairment.⁴⁴ Moreover, the modeling approach presented in this study can serve as a blueprint to develop PBPK models of other CYP2D6 substrates.

ACKNOWLEDGEMENTS

Open Access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST

The authors declared no competing interests for this work.

AUTHOR CONTRIBUTIONS

S.R., D.S., U.F., M.S., and T.L. wrote the manuscript. T.L., D.S., and S.R. designed the research. S.R. performed the research. S.R., D.S., and T.L. analyzed the data.

REFERENCES

- Guenin E, Armogida M, Riff D. Pharmacokinetic profile of dextromethorphan hydrobromide in a syrup formulation in children and adolescents. *Clin Drug Investig*. 2014;34:609-616.

- Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta[®]) clinical use. *Pharmacol Ther*. 2016;164:170-182.
- Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism. *J Clin Psychopharmacol*. 1998;18:332-337.
- Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. *AAPS J*. 2011;13:519-547.
- Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. *Clin Pharmacol Ther*. 1996;60:295-307.
- Lutz JD, Isoherranen N. Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole. *Drug Metab Dispos*. 2012;40:159-168.
- Schadel M, Wu D, Otton SV, Kalow W, Sellers EM. Pharmacokinetics of dextromethorphan and metabolites in humans. *J Clin Psychopharmacol*. 1995;15:263-269.
- Gorski JC, Huang S-M, Pinto A, et al. The effect of echinacea (*Echinacea purpurea* root) on cytochrome P450 activity in vivo. *Clin Pharmacol Ther*. 2004;75:89-100.
- FDA. FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. <https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table2-1>.
- Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. *Naunyn Schmiedebergs Arch Pharmacol*. 2004;369:23-37.
- Cicali EJ, Smith DM, Duong BQ, Kovar LG, Cavallari LH, Johnson JA. A scoping review of the evidence behind cytochrome P450 2D6 isoenzyme inhibitor classifications. *Clin Pharmacol Ther*. 2020;108:116-125.
- Chainuvati S, Nafziger AN, Steven Leeder J, et al. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the 'Cooperstown 5+1 cocktail'. *Clin Pharmacol Ther*. 2003;74:437-447.
- Ryu JY, Song IS, Sunwoo YE, et al. Development of the 'Inje cocktail' for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. *Clin Pharmacol Ther*. 2007;82:531-540.
- Pharmacogene Variation Consortium (PharmVar) CYP2D6 gene. *Gaedigk al*. 2018, *CPT 103399*; *Gaedigk al*. 2019, *CPT 10529* at <https://www.pharmvar.org/gene/CYP2D6>, (Gaedigk et al 2018, *CPT 103:399*; Gaedigk et al 2019, *CPT 105:29*).
- Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. *Clin Pharmacol Ther*. 2008;83:234-242.
- Gaedigk A, Dinh JC, Jeong H, Prasad B, Ten Leeder JS. years' experience with the CYP2D6 activity score: a perspective on future investigations to improve clinical predictions for precision therapeutics. *J Pers Med*. 2018;8:1-15.
- Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP 2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics

- implementation consortium and Dutch pharmacogenetics working group. *Clin Transl Sci*. 2020;13:116-124.
18. Lippert J, Burghaus R, Edginton A, et al. Open systems pharmacology community—an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. *CPT Pharmacometrics Syst Pharmacol*. 2019;8:878-882.
 19. Wojtyniak JG, Britz H, Selzer D, Schwab M, Lehr T. Data digitizing: accurate and precise data extraction for quantitative systems pharmacology and physiologically-based pharmacokinetic modeling. *CPT Pharmacometrics Syst Pharmacol*. 2020;9:322-331.
 20. Seabold S, Perktold J. Statsmodels: econometric and statistical modeling with Python. *Proc 9th Python Sci Conf*. 2010:92-96. <https://conference.scipy.org/proceedings/scipy2010/seabold.html>
 21. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the ‘cocktail’ approach. *Clin Pharmacol Ther*. 2007;81:270-283.
 22. Frank D. Bewertung von pharmakokinetischen Parametern zur Phänotypisierung des menschlichen Cytochrom P450 Enzyms CYP2D6 mittels Dextromethorphan. (2009). <https://bonndoc.ulb.uni-bonn.de/xmlui/bitstream/handle/20.500.11811/4056/1707.pdf?sequence=1&isAllowed=y>
 23. Open Systems Pharmacology Suite Community Open Systems Pharmacology Suite Manual, Version 7.4. (2018). <https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/master/OpenSystemsPharmacologySuite.pdf>
 24. Rüdeshheim S, Wojtyniak J-G, Selzer D, et al. Physiologically based pharmacokinetic modeling of metoprolol enantiomers and α -hydroxymetoprolol to describe CYP2D6 drug-gene interactions. *Pharmaceutics*. 2020;12:1200.
 25. Kazmi F, Hensley T, Pope C, et al. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). *Drug Metab Dispos*. 2013;41:897-905.
 26. Bolger MB, Macwan JS, Sarfraz M, Almukainzi M, Löbenberg R. The irrelevance of in vitro dissolution in setting product specifications for drugs like dextromethorphan that are subject to lysosomal trapping. *J Pharm Sci*. 2019;108:268-278.
 27. Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. *Drug Metab Dispos*. 2011;39:170-173.
 28. Thiel C, Schneckener S, Krauss M, et al. A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation. *J Pharm Sci*. 2015;104:191-206.
 29. Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Isoherranen N, Unadkat JD. A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. *Drug Metab Dispos*. 2013;41:801-813.
 30. Storelli F, Desmeules J, Daali Y. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes. *Basic Clin Pharmacol Toxicol*. 2019;124:170-180.
 31. Marcucci KA, Pearce RE, Crespi C, Steimel DT, Steven Leeder J, Gaedigk A. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bupropion, and debrisoquine. *Drug Metab Dispos*. 2002;30:595-601.
 32. Shen H, He MM, Liu H, et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. *Drug Metab Dispos*. 2007;35:1292-1300.
 33. Nofziger C, Turner AJ, Sangkuhlet K, et al. PharmVar GeneFocus: CYP2D6. *Clin Pharmacol Ther*. 2020;107:154-170.
 34. Bapiro TE, Hasler JA, Ridderström M, Masimirembwa CM. The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant: Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. *Biochem Pharmacol*. 2002;64:1387-1398.
 35. Heim M, Meyer U. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. *Lancet*. 1990;336:529-532.
 36. Lu S, Nand RA, Yang JS, Chen G, Gross AS. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects. *Eur J Clin Pharmacol*. 2018;74:285-296.
 37. Matthaei J, Brockmöller J, Tzvetkov MV, et al. Heritability of metoprolol and torsemide pharmacokinetics. *Clin Pharmacol Ther*. 2015;98:611-621.
 38. Thomas CD, Mosley SA, Kim S, et al. Examination of metoprolol pharmacokinetics and pharmacodynamics across CYP2D6 genotype-derived activity scores. *CPT Pharmacometrics Syst Pharmacol*. 2020;9:678-685.
 39. Gazzaz M, Kinzig M, Schaeffeler E, et al. Drinking ethanol has few acute effects on CYP2C9, CYP2C19, NAT2, and P-glycoprotein activities but somewhat inhibits CYP1A2, CYP2D6, and intestinal CYP3A: so what? *Clin Pharmacol Ther*. 2018;104:1249-1259.
 40. Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. *Eur J Clin Pharmacol*. 2007;63:321-333.
 41. Türk D, Hanke N, Lehr T. A physiologically-based pharmacokinetic model of trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 drug–drug–gene interaction predictions. *Pharmaceutics*. 2020;12:1074.
 42. Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. *Clin Pharmacokinet*. 2006;45:1013-1034.
 43. Schlender J-F, Meyer M, Thelen K, et al. Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals. *Clin Pharmacokinet*. 2016;55:1573-1589.
 44. Hanke N, Türk D, Selzer D, et al. A comprehensive whole-body physiologically based pharmacokinetic drug–drug–gene interaction model of metformin and cimetidine in healthy adults and renally impaired individuals. *Clin Pharmacokinet*. 2020;59:1419-1431.
 45. Duedahl TH, Dirks J, Petersen KB, et al. Intravenous dextromethorphan to human volunteers: relationship between pharmacokinetics and anti-hyperalgesic effect. *Pain*. 2005;113:360-368.
 46. Nakashima D, Takama H, Ogasawara Y, et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan. in vitro and clinical studies. *J Clin Pharmacol*. 2007;47:1311-1319.
 47. Khalilieh S, Hussain A, Montgomery D, et al. Effect of til-drakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in

- subjects with moderate to severe psoriasis. *Br J Clin Pharmacol*. 2018;84:2292-2302.
48. Nyunt MM, Becker S, MacFarland RT, et al. Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. *JAIDS J Acquir Immune Defic Syndr*. 2008;47:559-565.
49. Dumond JB, Vourvahis M, Rezk NL, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. *Clin Pharmacol Ther*. 2010;87:735-742.
50. Feld R, Woo MM, Leigh N, et al. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. *Cancer Chemother Pharmacol*. 2013;72:747-755.
51. Tennezé L, Verstuyft C, Becquemont L, Poirier JM, Wilkinson GR, Funck-Brentano C. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. *Clin Pharmacol Ther*. 1999;66:582-588.
52. Qiu F, Liu S, Miao P, et al. Effects of the Chinese herbal formula “Zuojin Pill” on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype. *Eur J Clin Pharmacol*. 2016;72:689-695.
53. Storelli F, Matthey A, Lenglet S, et al. Impact of CYP2D6 functional allelic variations on phenoconversion and drug-drug interactions. *Clin Pharmacol Ther*. 2018;104:148-157.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Rüdeshheim S, Selzer D, Fuhr U, Schwab M, Lehr T. Physiologically-based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups. *CPT Pharmacometrics Syst Pharmacol*. 2022;11:494-511. doi:[10.1002/psp4.12776](https://doi.org/10.1002/psp4.12776)